AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33130166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood greenness (measured by NDVI)
Number of subjects: 1178
Study 33130216 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT3833
Number of subjects: 1
Study 33130518 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT+/CD3+ lymphocytes in peripheral blood and tissue specimens
Number of subjects: 80
Study 33130518 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT+/CD3+/CD161+ lymphocytes in blood and cancer tissue
Number of subjects: 80
Study 33130518 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT cells in blood and intra-tumor NKT-cell infiltration
Number of subjects: 80
Study 33130518 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT cells in benign ovarian tumors
Number of subjects: 80
Study 33130518 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT cells in tumor tissue
Number of subjects: 80
Study 33130518 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125 serum marker
Number of subjects: 80
Study 33130518 — intervention group
Group type: EXPERIMENTAL
Intervention: NKT lymphocyte count from ovarian tissue
Number of subjects: 80
Study 33130556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up intraocular pressure (IOP) for G1 <21 mmHg
Number of subjects: 603
Study 33130556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up intraocular pressure (IOP) for G2 <18 mmHg
Number of subjects: 603
Study 33130556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up intraocular pressure (IOP) for G3 <15 mmHg
Number of subjects: 603
Study 33130556 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to treatment guidelines
Number of subjects: 603
Study 33130556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP for G1
Number of subjects: 603
Study 33130556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP for G2
Number of subjects: 603
Study 33130556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP for G3
Number of subjects: 603
Study 33130933 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant Removal (IR)
Number of subjects: 37
Study 33130961 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVmax
Number of subjects: 355
Study 33130961 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR
Number of subjects: 355
Study 33130961 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment using a five-point ordinal PET-grade
Number of subjects: 355
Study 33130961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PET/CT grade using CT features
Number of subjects: 355
Study 33131027 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5 or 10 mg) daily for 2 weeks
Number of subjects: 114
Study 33131027 — intervention group
Group type: EXPERIMENTAL
Intervention: IDSIQ-18
Number of subjects: 114
Study 33131027 — intervention group
Group type: COMPARATOR
Intervention: Good sleepers (observational study)
Number of subjects: 114
Study 33131249 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CLL subset #2 in early-stage cohort
Number of subjects: 2453
Study 33131249 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CLL subset #2 in advanced-stage cohort
Number of subjects: 2453
Study 33131249 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CLL subset #4
Number of subjects: 2453
Study 33131249 — intervention group
Group type: EXPERIMENTAL
Intervention: U-CLL subset #8
Number of subjects: 2453
Study 33131308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy
Number of subjects: 0
Study 33131426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Interventional Stroke Team (MIST)
Number of subjects: 228
Study 33131426 — intervention group
Group type: COMPARATOR
Intervention: Drip-and-ship (DS)
Number of subjects: 228
Study 33131426 — intervention group
Group type: COMPARATOR
Intervention: Mothership
Number of subjects: 228
Study 33131757 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk patients (ARISCAT score ≥26)
Number of subjects: 905
Study 33131757 — intervention group
Group type: COMPARATOR
Intervention: Lower risk patients (ARISCAT score <26)
Number of subjects: 905
Study 33131757 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 905
Study 33131757 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk patients
Number of subjects: 905
Study 33131912 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing Enterobacteriaceae infection
Number of subjects: 527
Study 33131912 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (empirical antibiotic)
Number of subjects: 527
Study 33131912 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro-active antibiotics
Number of subjects: 527
Study 33131933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hantavax® (three primary doses and a booster dose schedule at 0, 1, 2 and 13 months)
Number of subjects: 320
Study 33131933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hantavax® (booster dose at 13 months)
Number of subjects: 320
Study 33131933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hantavax® (three primary doses)
Number of subjects: 320
Study 33131933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hantavax® (booster doses)
Number of subjects: 320
Study 33132098 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy vascular aging (HVA) estimated by heart age (HA)
Number of subjects: 501
Study 33132098 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy vascular aging (HVA) estimated by vascular age (VA)
Number of subjects: 501
Study 33132297 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Men-ACWY-D vaccine administered 8 weeks apart
Number of subjects: 60
Study 33134423 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate for 6 months
Number of subjects: 0
Study 33134423 — intervention group
Group type: COMPARATOR
Intervention: Control group (ART-naïve people with HIV)
Number of subjects: 0
Study 33134951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized DAS181 (4.5 mg) twice a day for 10 days
Number of subjects: 3
Study 33135120 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based self-reported activity
Number of subjects: 366
Study 33135120 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatically-generated smartphone-based activity measurements
Number of subjects: 366
Study 33135120 — intervention group
Group type: COMPARATOR
Intervention: Daily self-reported activity in patients with BD
Number of subjects: 366
Study 33135120 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (number of steps) in patients with BD
Number of subjects: 366
Study 33135120 — intervention group
Group type: COMPARATOR
Intervention: Social activity (missed calls) in patients with BD
Number of subjects: 366
Study 33135120 — intervention group
Group type: COMPARATOR
Intervention: Call duration in patients with BD
Number of subjects: 366
Study 33135120 — intervention group
Group type: COMPARATOR
Intervention: Physical activity in unaffected relatives (UR)
Number of subjects: 366
Study 33135120 — intervention group
Group type: COMPARATOR
Intervention: Daily self-reported activity in unaffected relatives (UR)
Number of subjects: 366
Study 33135120 — intervention group
Group type: COMPARATOR
Intervention: Social activity in unaffected relatives (UR)
Number of subjects: 366
Study 33135537 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast bath (CB)
Number of subjects: 20
Study 33135537 — intervention group
Group type: COMPARATOR
Intervention: Control group (without CRPS)
Number of subjects: 20
Study 33135728 — intervention group
Group type: EXPERIMENTAL
Intervention: 12,13-diHOME in human milk
Number of subjects: 58
Study 33135811 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised early intervention (SEI) teams
Number of subjects: 1145
Study 33135811 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1145
Study 33135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended SEI
Number of subjects: 780
Study 33136058 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable Amoxicillin every 12 hours plus once-daily injectable Gentamicin
Number of subjects: 308
Study 33136058 — intervention group
Group type: COMPARATOR
Intervention: Injectable Ampicillin every 6 hours plus once-daily injectable Gentamicin
Number of subjects: 308
Study 33136058 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable Amoxicillin plus Gentamicin
Number of subjects: 308
Study 33136507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 0
Study 33137019 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO MicroShunt implantation with adjunctive mitomycin C (0.4 mg/mL)
Number of subjects: 23
Study 33137021 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour contact lens sensor (CLS, Triggerfish) recording of intraocular pressure (IOP)-related ocular dimensional changes
Number of subjects: 32
Study 33137293 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide (open-label for 12 weeks, followed by an 8-week placebo-controlled withdrawal sequence and 32 weeks of open-label treatment)
Number of subjects: 21
Study 33137635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual head positioning (GHP) changes from 5-min FLAT to SIT head position
Number of subjects: 0
Study 33137635 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT head position after 5-min
Number of subjects: 0
Study 33137635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study 33138623 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 0
Study 33138835 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BC on treatment post-surgery (Group 1, 89 patients)
Number of subjects: 299
Study 33138835 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BC after completion of adjuvant treatment (Group 2, 108 patients)
Number of subjects: 299
Study 33138835 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic BC treatment (Group 3, 102 patients)
Number of subjects: 299
Study 33138839 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS patients requiring mechanical ventilation (MV)
Number of subjects: 28
Study 33138839 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and ELF CXCL10 concentrations
Number of subjects: 28
Study 33138839 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF concentrations of mitochondrial DNA
Number of subjects: 28
Study 33138839 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory mediators in COVID-19 ARDS
Number of subjects: 28
Study 33138839 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL10 as a candidate biomarker
Number of subjects: 28
Study 33138848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing antivirals (β-cyclodextrin and Citrox®)
Number of subjects: 206
Study 33138848 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 206
Study 33138866 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib at a starting dose of 100 mg daily
Number of subjects: 50
Study 33138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation for a median time of 11 days (IQR 6-14)
Number of subjects: 164
Study 33138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressors
Number of subjects: 164
Study 33138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Number of subjects: 164
Study 33138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (OR, 1.05; 95% CI, 1.02-1.08; p<0.001)
Number of subjects: 164
Study 33138974 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels upon ICU admission (1.008; 95% CI, 1.003-1.012; p<0.001)
Number of subjects: 164
Study 33138974 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 164
Study 33139055 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib + Itraconazole (Cycle 1)
Number of subjects: 0
Study 33139055 — intervention group
Group type: COMPARATOR
Intervention: Volasertib monotherapy (Cycle 2)
Number of subjects: 0
Study 33139139 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine with Matrix-M™ adjuvant
Number of subjects: 0
Study 33139139 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 0
Study 33139266 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity
Number of subjects: 30
Study 33139266 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 30
Study 33139350 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase enzyme replacement therapy (ERT)
Number of subjects: 740
Study 33139350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 740
Study 33139350 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 740
Study 33139388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Chemistry Score (CCS) using Ortho Clinical Diagnostics high-sensitivity cardiac troponin I (hs-cTnI) assay in cohort 1
Number of subjects: 0
Study 33139388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Chemistry Score (CCS) using Abbott Diagnostics hs-cTnI assay in cohort 2
Number of subjects: 0
Study 33139388 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnI alone (published cut-offs)
Number of subjects: 0
Study 33140173 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-targeted fluid resuscitation (CRT-T)
Number of subjects: 42
Study 33140173 — intervention group
Group type: COMPARATOR
Intervention: Lactate-targeted fluid resuscitation (LAC-T)
Number of subjects: 42
Study 33140460 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days of nicotinised cigarette smoking
Number of subjects: 27
Study 33140460 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cigarette smoking (nicotinised)
Number of subjects: 27
Study 33140460 — intervention group
Group type: COMPARATOR
Intervention: Exposure to smoking-related cues
Number of subjects: 27
Study 33140664 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib (INCB050465), a highly selective PI3Kδ inhibitor, used as monotherapy.
Number of subjects: 0
Study 33140664 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 33141094 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote titration facilitated by a smartphone-based telemonitoring system
Number of subjects: 42
Study 33141094 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 42
Study 33141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (n=10)
Number of subjects: 30
Study 33141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic exercise group (n=10)
Number of subjects: 30
Study 33141101 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual group (n=10)
Number of subjects: 30
Study 33141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-Stand test
Number of subjects: 30
Study 33141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of circulating cell-free DNA and extracellular vesicles
Number of subjects: 30
Study 33141103 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-week online intervention for increasing physical activity
Number of subjects: 79
Study 33141103 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 79
Study 33141170 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 4668
Study 33141170 — intervention group
Group type: COMPARATOR
Intervention: Not treated
Number of subjects: 4668
Study 33141170 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating treatment
Number of subjects: 4668
Study 33141172 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-flortaucipir PET
Number of subjects: 20
Study 33141172 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal controls
Number of subjects: 20
Study 33141188 — intervention group
Group type: EXPERIMENTAL
Intervention: RESILIA aortic bioprosthesis
Number of subjects: 133
Study 33141449 — intervention group
Group type: COMPARATOR
Intervention: Phlebotonics (various types including rutosides, hidrosmine, diosmine, calcium dobesilate, etc.)
Number of subjects: 7690
Study 33141449 — intervention group
Group type: COMPARATOR
Intervention: Phlebotonics
Number of subjects: 7690
Study 33142006 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app with personalized plasma renin activity (PRA) recommendations; clinicians followed app's recommendations (n=16, 55%)
Number of subjects: 29
Study 33142006 — intervention group
Group type: COMPARATOR
Intervention: Smartphone app with personalized plasma renin activity (PRA) recommendations; clinicians did not follow app's recommendations (n=13, 45%)
Number of subjects: 29
Study 33142018 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of efflux transporter inhibitors
Number of subjects: 0
Study 33142018 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapeutics that cause CIPN (taxanes, platins, vincristine, bortezomib, epothilones, thalidomide)
Number of subjects: 0
Study 33142018 — intervention group
Group type: COMPARATOR
Intervention: Genetic variants in efflux transporters
Number of subjects: 0
Study 33142029 — intervention group
Group type: EXPERIMENTAL
Intervention: p16/Ki-67 assay
Number of subjects: 3100
Study 33142068 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transfer (FMT) - three repeated FMTs (day 0, two weeks, four weeks)
Number of subjects: 9
Study 33142850 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor program activating therapy
Number of subjects: 44
Study 33142850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta's reflex locomotion
Number of subjects: 44
Study 33142850 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 33143665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit® activity monitor and 'Bupa Boost' smartphone app
Number of subjects: 180
Study 33144080 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33144166 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged home
Number of subjects: 1902
Study 33144166 — intervention group
Group type: COMPARATOR
Intervention: Discharged to rehabilitation clinic or another institution
Number of subjects: 1902
Study 33144239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE) antegrade approach
Number of subjects: 30
Study 33144239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE) bidirectional approach
Number of subjects: 30
Study 33144352 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma MGO levels
Number of subjects: 160
Study 33145060 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic COPD (blood eosinophil counts ≥300 cells/µL)
Number of subjects: 145
Study 33145060 — intervention group
Group type: COMPARATOR
Intervention: Non-eosinophilic COPD (blood eosinophil counts <300 cells/µL)
Number of subjects: 145
Study 33145266 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib, 500 mg once daily, until disease progression, unacceptable toxicity, consent withdrawal, or death.
Number of subjects: 23
Study 33145402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 1184
Study 33145402 — intervention group
Group type: COMPARATOR
Intervention: HER2 amplification-positive patients
Number of subjects: 1184
Study 33145494 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study 33145494 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 33145616 — intervention group
Group type: EXPERIMENTAL
Intervention: Berzosertib (intravenous infusion)
Number of subjects: 240
Study 33145694 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies bundle (team activation, external facilitation, community of practice)
Number of subjects: 0
Study 33145694 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of central champions in facilities
Number of subjects: 0
Study 33145809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose CT (LDCT) imaging for osteoporosis screening
Number of subjects: 69095
Study 33146624 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized discharge prescription forms with 90-day prescriptions and 3 repeats for recommended cardiac medication classes, in combination with education
Number of subjects: 0
Study 33146624 — intervention group
Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 0
Study 33146624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33146624 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer (>60 days) versus shorter prescription durations
Number of subjects: 0
Study 33146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel DNA-based diagnostic assay for CNS infections
Number of subjects: 300
Study 33146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR-based meningitis/encephalitis (ME) panel
Number of subjects: 300
Study 33146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomics profiling of blood from children with severe CNS infection
Number of subjects: 300
Study 33146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Myxovirus resistance protein A (MxA) as a biomarker in blood for viral CNS infection
Number of subjects: 300
Study 33146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine against Streptococcus pneumoniae
Number of subjects: 300
Study 33146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage and invasive rate of Neisseria meningitidis
Number of subjects: 300
Study 33146741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 250 mg every 3 weeks
Number of subjects: 13
Study 33146741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks
Number of subjects: 13
Study 33146812 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II papillae
Number of subjects: 637
Study 33146812 — intervention group
Group type: EXPERIMENTAL
Intervention: Type IIIb papillae
Number of subjects: 637
Study 33146812 — intervention group
Group type: COMPARATOR
Intervention: Type I papillae
Number of subjects: 637